CHEN, Aiqi. CD19 And CD22 Dual-Target CAR-T Therapy Via CRISPR/Cas9 Engineering for Relapsed B-Cell Acute Lymphoblastic Leukemia. Academic Journal of Science and Technology, [S. l.], v. 18, n. 1, p. 621–625, 2025. DOI: 10.54097/79zwp242. Disponível em: https://drpress.org/ojs/index.php/ajst/article/view/33145. Acesso em: 7 jul. 2026.